Data enabling evaluation of icatibant‐treated attack characteristics was available for 61 patients (214 attacks) with HAE with C1 INH deficiency (type I), three patients (11 attacks) in the HAE with C1 INH dysfunction (type II) group, and 10 patients (90 attacks) in the HAE‐nC1 INH group (Table 2). This evidence concerns the gene SERPING1 and hereditary angioedema.